Skip to main content
. 2021 Dec 5;8:100185. doi: 10.1016/j.resplu.2021.100185

Table 1.

Baseline characteristics differentiated by sex. Median and interquartile differences are reported for continuous covariates, and absolute numbers with relative category frequencies are shown for categorical covariates.χ2tests were used to compare categorical variables and Kruskal–Wallis tests for continuous variables.

Admission
Discharge
Covariates Cohort Men Women P value Cohort Men Women P value
Number Patients 2,278 1,357 921 970 592 378
Age (Years) 61 (21.0) 61 (20.0) 60 (23.0) 0.748 61 (19.0) 61 (16.25) 60 (23.00) 0.339
CCI 1.0 (3.0) 1 (3.0) 1 (2.0) 0.248 1.0 (2.0) 1.0 (2.0) 1.0 (2.0) 0.405
Arrest out-of-hospital (%) 1748 (76.73) 1028 (75.76) 720 (78.18) 0.197 702 (72.47) 424 (71.62) 279 (73.81) 0.503
Initial VT/VFa (%) 772 (33.89) 497 (36.62) 275 (29.86) 0.001 490 (50.52) 316 (53.38) 174 (46.03) 0.030
Etiology (%) < 0.001 0.001
ACSb 353 (15.50) 239 (17.61) 114 (12.38) 219 (22.58) 159 (26.86) 60 (15.87)
Respiratory 341 (14.97) 169 (12.45) 172 (18.68) 121 (12.47) 67 (11.32) 54 (14.29)
Other cardiacc 371 (16.29) 229 (16.88) 142 (15.42) 218 (22.47) 125 (21.11) 93 (24.60)
Other non cardiacd 642 (28.18) 365 (26.90) 277 (30.08) 242 (24.95) 134 (22.64) 108 (28.57)
Unknown 571 (25.07) 355 (26.16) 216 (23.45) 170 (17.53) 107 (18.07) 63 (16.67)
Arrest duration (Minutes) 12 (21.0) 12 (21.0) 13 (21.0) 0.841 8 (12.5) 8 (12.0) 6.5 (13.0) 0.863
Bystander CPRe (%) 1108 (48.64) 664 (48.93) 444 (48.21) 0.752 413 (42.58) 259 (43.75) 154 (40.74) 0.148
Witnessed (%) 1025 (45.02) 624 (45.98) 401 (43.59) 0.526 419 (43.20) 270 (45.61) 149 (39.42) 0.159
Epinephrine (Number of doses) 2 (3.0) 2 (3.0) 2 (3.0) 0.248 1 (2.0) 1 (2.0) 1 (2.0) 0.578
PCACf (%) 0.105 0.374
1 534 (25.99) 318 (25.75) 216 (26.34) 463 (52.14) 274 (50.46) 189 (54.78)
2 399 (19.42) 261 (21.13) 138 (16.83) 267 (30.07) 174 (32.04) 93 (26.96)
3 204 (9.93) 117 (9.47) 87 (10.61) 93 (10.47) 58 (10.68) 35 (10.14) v
4 918 (44.67) 539 (43.64) 379 (46.22) 65 (7.32) 37 (6.81) 28 (8.12)
Catheterization (%) 596 (26.16) 390 (28.74) 206 (22.37) 0.001 412 (42.47) 275 (46.45) 137 (36.24) 0.002
Temperature Treatment (%) 0.695 0.565
36 °C 644 (28.27) 370 (27.27) 274 (29.75) 244 (25.15) 147 (24.83) 97 (25.66)
33 °C 767 (33.67) 472 (34.78) 295 (32.03) 204 (21.03) 135 (22.80) 69 (18.25)
Active Normothermia 31 (1.36) 18 (1.33) 13 (1.41) 13 (1.34) 7 (1.18) 6 (1.59)
No TTMg 694 (30.47) 409 (30.14) 285 (30.94) 458 (47.22) 270 (45.61) 188 (49.74)
Otherh 142 (6.23) 88 (6.48) 54 (5.87) 51 (5.26) 33 (5.58) 18 (4.76)
a

Ventricular Tachycardia or Fibrillation.

b

Acute Coronary Syndrome.

c

Intrinsic arrythmia, arrythmia secondary to cardiomyopathy, structural heart disease, left ventricule failure, right ventricule failure.

d

Toxicological, airway obstruction, exsanguination, distributive shock, metabolic derangement.

e

Cardio Pulmonary resuscitation.

f

Pittsburgh Cardiac Arrest Category.

h

Other targeted temperature.

g

Temperature Treatment Management.

Charlson Comorbidity Index.